The estimated Net Worth of Robert Silverman is at least $709 ezer dollars as of 9 March 2017. Robert Silverman owns over 30,966 units of Concert Pharmaceuticals Inc stock worth over $427,498 and over the last 10 years Robert sold CNCE stock worth over $281,750.
Robert has made over 9 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Robert exercised 30,966 units of CNCE stock worth $34,992 on 9 March 2017.
The largest trade Robert's ever made was exercising 30,966 units of Concert Pharmaceuticals Inc stock on 9 March 2017 worth over $34,992. On average, Robert trades about 7,244 units every 78 days since 2014. As of 9 March 2017 Robert still owns at least 51,075 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Robert Silverman stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... és Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: